Holzer Holzer & Fistel, LLC Announces Investigation Into ViroPharma Incorporated

Holzer Holzer & Fistel, LLC is investigating potential violations of the federal securities laws by ViroPharma Incorporated (“ViroPharma” or the “Company”) (NASDAQ: VPHM). The investigation focuses on whether a series of statements made between December 14, 2011 and April 9, 2012, inclusive, regarding ViroPharma’s business, its prospects and its operations were materially false and misleading at the time they were made. Specifically, the investigation seeks to determine, among other things, whether ViroPharma knew but failed to adequately and timely disclose that its sNDA for Vancocin did not provide for any significant new use or indication for the drug and, as a result, Vancocin would not be eligible to receive an additional three years of exclusivity.

If you purchased ViroPharma common stock between December 14, 2011 and April 9, 2012 and have questions concerning your legal rights, you are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel, Jr., Esq. or Marshall P. Dees, Esq. via email at [e-mail], or [e-mail], or via toll-free telephone at [phone].

Holzer Holzer & Fistel, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.

Copyright Business Wire 2010